Leslie Burton
Nurse Practitioner · Tulsa, OKNPI 1699323097
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$831
- Novartis$720
- E.r. Squibb & Sons, L.L.C.$614
- Amgen$522
- Johnson & Johnson$454
- Esperion Therapeutics, Inc.$367
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,34398%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 47 | $831 |
| Novartis | 50 | $720 |
| E.r. Squibb & Sons, L.L.C. | 35 | $614 |
| Amgen | 30 | $522 |
| Johnson & Johnson | 24 | $454 |
| Esperion Therapeutics, Inc. | 20 | $367 |
| Boston Scientific | 12 | $352 |
| Pfizer | 20 | $351 |
| Actelion Pharmaceuticals US, Inc. | 8 | $347 |
| Boehringer Ingelheim | 16 | $277 |
| Bayer | 14 | $255 |
| AstraZeneca | 13 | $229 |
| Alnylam Pharmaceuticals Inc. | 9 | $217 |
| Sanofi-aventis U.S. LLC | 8 | $150 |
| Amarin Pharma, Inc. | 8 | $132 |
| Philips North America LLC | 5 | $100 |
| Azurity Pharmaceuticals, Inc. | 4 | $78 |
| Novo Nordisk | 4 | $70 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| Impulse Dynamics (USA) Inc. | 4 | $58 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $51 |
| Cvrx, Inc. | 2 | $37 |
| Kestra Medical Technology Services, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 2 | $29 |
| Althera Pharmaceuticals LLC | 2 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,443 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 400 | $444,145 |
| XareltoRivaroxaban | 135 | $155,981 |
| EntrestoSacubitril/Valsartan | 49 | $67,627 |
| FarxigaDapagliflozin Propanediol | 38 | $47,753 |
| Repatha SureclickEvolocumab | 44 | $47,121 |
| JardianceEmpagliflozin | 23 | $30,598 |
| MultaqDronedarone Hcl | 21 | $26,391 |
| Praluent PenAlirocumab | 17 | $12,351 |
| BrilintaTicagrelor | 19 | $9,644 |
| Ezetimibe | 186 | $7,281 |
| Atorvastatin Calcium | 371 | $5,907 |
| Metoprolol Succinate | 384 | $5,836 |
| Potassium Chloride | 123 | $4,686 |
| Amiodarone Hcl | 161 | $3,783 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $3,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $351 | $444,145400 claims |
| Johnson & JohnsonXarelto | $454 | $155,981135 claims |
| NovartisEntresto | $720 | $67,62749 claims |
| AstraZenecaFarxiga, Brilinta | $229 | $57,39757 claims |
| Boehringer IngelheimJardiance | $277 | $30,59823 claims |
| Sanofi-aventis U.S. LLCMultaq | $150 | $26,39121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Tulsa
- Jenny GuthrieTulsa$106K
- Stacy NewberryTulsa$28K
- Amanda SmallTulsa$14K
- Mindi PriceTulsa$11K
- Huong HuynhTulsa$10K
- Jonathan BouldinTulsa$10K
- Michelle LoeberTulsa$10K
- Erin WilliamsonTulsa$9K
- Andrea CarpenterTulsa$7K
- Charles SpradlinTulsa$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.